To access this element change to forms mode OFF
Grant Award View - GA30032
Macrophages as novel targets for ameliorating deleterious complement...
GA ID:
GA30032
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2022
Value (AUD):
$827,362.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Macrophages as novel targets for ameliorating deleterious complement activation in retinal degeneration
Purpose:
Age-related macular degeneration (AMD) is the most common cause of blindness in Australia, although there few effective treatments. Without fresh understanding into its underlying cause, its incidence is expected to double by 2030. This research will lend new insight into how innate immune pathways drive noxious inflammation in AMD, which will help guide the development of novel antiinflammatory therapeutics to help ease its socio-economic burden on Australians.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1165599
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC
Postcode:
Multiple
Country:
AUSTRALIA